

### AMENDMENTS TO THE CLAIMS

1. (original) A system for treating an individual experiencing a chronic physiologic condition that is characterized by abnormal levels of cytokines or other species of pro-inflammatory or anti-inflammatory stimulators or mediators in the blood, the system comprising a material that removes cytokines or other species of pro-inflammatory or anti-inflammatory stimulators or mediators from blood by selective adsorption, and means for circulating the blood of the individual through the material.

2. (original) A system according to claim 1  
further including means for administering an agent to the individual selected to treat the chronic physiologic condition.

3. (original) A system according to claim 1  
wherein the means for circulating includes an intravenous catheter.

4. (original) A system according to claim 1  
wherein the means for circulating includes an indwelling catheter.

5. (original) A system according to claim 1  
wherein the means for circulating includes tubing having a wall impregnated with the material.

6. (original) A system according to claim 1  
wherein the means for circulating includes an in-line housing, and  
wherein the material is contained within the housing.

7. (original) A system according to claim 1  
wherein the means for circulating includes an in-line exchangeable housing, and  
wherein the material is contained within the housing.

8. (original) A system according to claim 1  
wherein the means for circulating and the material are sized to be carried with the individual during ambulation.

9. (original) A system according to claim 1  
wherein the material is characterized by a Biocompatibility Index of not greater than 14.

10. (original) A system according to claim 9  
wherein the Biocompatibility Index is not greater than 7.

11. (original) A system according to claim 1

wherein the material comprises a polymeric material.

12. (original) A system according to claim 11

wherein the polymeric material comprises particles prepared by polymerization or copolymerization of a monomer selected from a group consisting of styrene, ethylstyrene,  $\alpha$ -methylstyrene, divinylbenzene, di isopropenyl benzene, trivinylbenzene, and alkyl methacrylate.

*prod - by - process*

13. (original) A system according to claim 11

wherein the polymeric material comprises particles formed from crosslinked polystyrene-type resins having a surface modified to minimize activation of blood complement system.

14. (original) A system according to claim 11

wherein the polymeric material comprises particles formed from a porous hydrophobic divinylbenzene copolymer having a surface modified to include surface exposed functional groups selected from the group of polymers of 2-hydroxyethyl methacrylate, N-vinylpyrrolidine, N-vinylcaprolactame and N-acrylamide.

15. (original) A system according to claim 11

wherein the polymeric material comprises particles formed by polymerization of aromatic divinyl compounds or their copolymerization with aromatic monovinyl compounds in the presence of porogens or mixtures of porogens with properties close to those of  $\theta$ -solvents.

16 - 61 (cancelled).

62. (original) A system for treating an individual experiencing trauma before onset of septic shock comprising a material that removes cytokines or other species of pro-inflammatory or anti-inflammatory stimulators or mediators from blood by selective adsorption, and means for circulating the blood of the individual through the material.

63. (original) A system according to claim 62

further including means for administering an agent to the individual selected to treat trauma.

64. (original) A system according to claim 62

wherein the means for circulating includes an intravenous catheter.

65. (original) A system according to claim 62

wherein the means for circulating includes an indwelling catheter.

66. (original) A system according to claim 62

wherein the means for circulating includes tubing having a wall impregnated with the material.

67. (original) A system according to claim 62

wherein the means for circulating includes an in-line housing, and  
wherein the material is contained within the housing.

68. (original) A system according to claim 62

wherein the means for circulating includes an in-line exchangeable housing, and  
wherein the material is contained within the housing.

69. (original) A system according to claim 68

wherein the means for circulating and the material are sized to be carried with the individual  
during ambulation.

70. (original) A system according to claim 62

wherein the material is characterized by a Biocompatibility Index of not greater than 14.

71. (original) A system according to claim 70

wherein the Biocompatibility Index is not greater than 7.

72. (original) A system according to claim 62

wherein the material comprises a polymeric material.

73. (original) A system according to claim 72

wherein the polymeric material comprises particles prepared by polymerization or  
copolymerization of a monomer selected from a group consisting of styrene, ethylstyrene,  $\alpha$ -  
methylstyrene, divinylbenzene, di isopropenyl benzene, trivinylbenzene, and alkyl methacrylate.

74. (original) A system according to claim 72

wherein the polymeric material comprises particles formed from crosslinked polystyrene-  
type resins having a surface modified to minimize activation of blood complement system.

75. (original) A system according to claim 72

wherein the polymeric material comprises particles formed from a porous hydrophobic  
divinylbenzene copolymer having a surface modified to include surface exposed functional groups  
selected from the group of polymers of 2-hydroxyethyl methacrylate, N-vinylpyrrolidine, N-  
vinylcaprolactame and N-acrylamide.

76. (original) A system according to claim 72

wherein the polymeric material comprises particles formed by polymerization of aromatic  
divinyl compounds or their copolymerization with aromatic monovinyl compounds in the presence  
of porogens or mixtures of porogens with properties close to those of  $\theta$ -solvents.

*Al*  
*Concl'd* 77-92 (cancelled).

---